Clinical trial · Observational

Study of Tumor Tissue From Patients With Melanoma Treated on Clinical Trial EST-1690

Molecular Prognostic Factor Analysis in Melanoma

NCT00937781CI-TRIAL-00027604completedClinicalTrials.gov clinicaltrialsPublishedExplore in graph →

Summary

Brief summary (as posted)

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at tumor tissue samples from patients with melanoma treated on clinical trial EST-1690.

Conditions

Conditions (1)

Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.

Condition (as posted)	Mapped entity	Match	Confidence
Melanoma (Skin)	Melanoma	ONTOLOGY_EXACT	0.85

Interventions

Interventions (6)

Intervention	Type	Mapped drug	Match
gene expression analysis	Genetic	—	UNRESOLVED
immunohistochemistry staining method	Other	—	UNRESOLVED
laboratory biomarker analysis	Other	—	UNRESOLVED
microarray analysis	Genetic	—	UNRESOLVED
polymerase chain reaction	Genetic	—	UNRESOLVED
RNA analysis	Genetic	—	UNRESOLVED

Design

Arms and outcomes

Arms (0)

[]

Primary outcomes (1)

measure
Prognostic role of several biomarkers on the outcome associated with melanoma using IHC
timeFrame
1 month

Eligibility

Eligibility (as posted)

Sex: All
Minimum age: 18 Years
Maximum age: 70 Years

Show eligibility criteria text

DISEASE CHARACTERISTICS:

* Diagnosis of melanoma

  * No metastatic disease at diagnosis
* Treated on protocol EST-1690
* Primary tumor tissue specimens available

PATIENT CHARACTERISTICS:

* Not specified

PRIOR CONCURRENT THERAPY:

* See Disease Characteristics

References

Publications (0)

Data not yet available

No reference posted for this study.